丹参酮ⅡA磺酸钠注射液对冠心病心衰炎性因子及BNP的影响

Influence of Tanshinone ⅡA sulfonate injection on inflammatory factors for coronary heart disease heart failure and BNP

目的:探讨丹参酮IIA磺酸钠注射液对冠心病心衰炎性因子及BNP的影响。方法:从入住心内科的病人中筛选符合冠心病心力衰竭的病人60例,其中心功能III级30例,心功能VI级30例;随机分成两组,常规治疗组和丹参酮IIA组。于治疗前、治疗1个疗程(14d)后测定血浆BNP浓度、CRP水平、IL-6水平。结果:应用丹参酮IIA磺酸钠注射液组的血浆炎性因子IL-6、CRP较对照组明显下降且BNP浓度亦明显下降(P<0.05),具有统计学意义。结论:丹参酮IIA磺酸钠注射液可显著降低冠心病心衰患者的血浆炎性因子IL-6、CRP水平,且降低冠心病心衰患者的血浆BNP浓度,有益于冠心病心衰的治疗。

Objective:To explore influence of Tanshinone IIA sulfonate injection on inflammatory factors of coronary heart disease heart failure and BNP. Methods:Check 60 cardiology patients with coronary heart disease heart failure;with 30 cases of NYHA III, 30 cases of NYHA IV; 60 cases were divided into the conventional treatment group and Tanshinone IIA group. Before treatment and after treatment, a course of treatment (14 days) plasma BNP levels, CRP levels, IL-6 levels. Results:The plasma inflammatory cytokines IL-6, CRP of Tanshinone IIA sulfonate injection group decreased more significantly compared with the control group and BNP concentrations also decreased more significantly (P<0.05), with statistical significance. Conclusion:Tanshinone IIA sulfonate injection can significantly reduce plasma inflammatory cytokines IL-6, CRP levels of coronary heart disease patients with heart failure and reduce plasma BNP concentrations, conducive to coronary heart failure treatment.